Discovery of novel Syk/PDGFR-α/c-Kit inhibitors as multi-targeting drugs to treat rheumatoid arthritis.
Bioorg Med Chem
; 26(15): 4375-4381, 2018 08 15.
Article
en En
| MEDLINE
| ID: mdl-30078608
ABSTRACT
Due to the complex biological pathways involved in rheumatoid arthritis, discovery of multi-targeting small molecules provides an effective strategy to achieve better efficacy and lower toxicity. Herein the first Syk/PDGFR-α/c-Kit inhibitors were designed and evaluated. Dihydrofuropyrimidine derivative 13 showed potent inhibitory activity against the three targets. Importantly, compound 13 exhibited good cellular efficacy against fibroblast-like synoviocytes (IC50â¯=â¯3.21⯵M) and mouse bone marrow-derived mast cells (IC50â¯=â¯2.03⯵M) and significantly decreased the secretion of inflammatory cytokines. Thus, Syk/PDGFR-α/c-Kit triple inhibitor 13 represented a promising lead compound for the treatment of RA.
Palabras clave
Texto completo:
1
Bases de datos:
MEDLINE
Asunto principal:
Artritis Reumatoide
/
Proteínas Proto-Oncogénicas c-kit
/
Receptor alfa de Factor de Crecimiento Derivado de Plaquetas
/
Inhibidores de Proteínas Quinasas
/
Proliferación Celular
/
Quinasa Syk
Tipo de estudio:
Prognostic_studies
Límite:
Animals
/
Humans
Idioma:
En
Revista:
Bioorg Med Chem
Asunto de la revista:
BIOQUIMICA
/
QUIMICA
Año:
2018
Tipo del documento:
Article